Defense Supply Center Philadelphia, Attn: DSCP-M Bldg 9-4, 2800 S. 20th Street, Philadelphia, PA 19145-5099

65 -- PROTON PUMP INHIBITORS SOL SP0200-99-R-1504 DUE 010899 POC Stephen Lewis, Contract Specialist (215)737-5649 and Mike McKeown, Contracting Officer, (215)737-5746 WEB: DSCP Home Page, http://www.dscp.dla.mil. E-MAIL: email address is the Contracting Officer, Mike McKeown, The Agency POC is mcmkeown@dscp.dla.mil or slewis@dscp.dla.mil. The Defense Supply Center Philadelphia(DSCP) intends to issue a solicitation for a single proton pump inhibitor(PPI) for the Department of Defense(DoD) Basic Core Formulary(BCF), National Mail Order Formulary and all DoD Medical Treatment Facility Formularies. The PPI class will be closed on all DoD formularies. The PPI must be FDA approved as of the issuance date of the solicitation. At the time of issuance of dscpthis notice, DSCP is aware of only the following PPI's, as identified in Physicians' Desk Reference, 42nd edition, 1998, lansoprazole and omeprazole. Prior to issuance of the solicitation, pharmaceutical companies are hereby invited, but not required,to make a presentation about the clinical attributes of their PPI at the DoD Pharmaeconomic Center(PEC), Fort Sam Houston, TX between 30 November and 3 December 1998. Information received during these presentations will assist in identifying the specifications and evaluation factors that will be used to determine the manufacturers that will meetthe yet to be defined requirements of the solicitation. One presentation will be scheduled for each PPI. Each presentation will be limited to no more than one hour. Companies may schedule their presentations by contacting MAJ Donald DeGroff at the DoD PEC, (210)295-9635 or (210) 295-1271. Pharmaceutical companies are encouraged to provide the following information regarding their product: (1) the efficacy, effectiveness, and dose distribution of the PPI in accute and maintenance phrases treatment of gastroesophageal reflux disease, preferably in head-to-head comparisons with the other PPI, using intent-to-treat and per protocol analysis; (2) comparative dose equivalence studies of the PPIs; (3) the incidence and severity of adverse effects at various dosage levels; (4) the propensity to cause drug interactions at various dosage levels; and (5) information pertaining to clinically significant differences between the PPI and the other PPI. NOTE: The Government may use information provided during the presentations when drafting its solicitation. All awards will based on the offers received in response to the actual solicitation and the evaluation criteria set forth therein. For assistance in interpeting the CBD announcement, please see the CBD Readers's Guide. Posted 10/30/98 (W-SN266907). (0303)

Loren Data Corp. http://www.ld.com (SYN# 0175 19981103\65-0001.SOL)